Reported is a case of a 58-year-old female treated in the past with cytostatics and rituximab for follicular lymphoma , in whom HBV infection was detected during a follow-up of the contacts of her partner diagnosed with acute viral hepatitis B. At the beginning , the patient had a very high serum level of HBV DNA ( 4.3 × 108 IU/mL ) and therefore she was treated with combined antiviral therapy ( lamivudine and tenofovir ) .
[Viral hepatitis B in a patient with follicular lymphoma treated with biological therapy]. Reactivation, recurrence or acute infection with hepatitis B virus (HBV) represent severe complications of biological therapy. Reported is a case of a 58-year-old female treated in the past with cytostatics and rituximab for follicular lymphoma , in whom HBV infection was detected during a follow-up of the contacts of her partner diagnosed with acute viral hepatitis B. At the beginning , the patient had a very high serum level of HBV DNA ( 4.3 × 108 IU/mL ) and therefore she was treated with combined antiviral therapy ( lamivudine and tenofovir ) . After 10 months, the serum level of HBV DNA decreased significantly (3,100 IU/mL) and the combined antiviral therapy was switched to monotherapy with tenofovir. Another 5 months later, the serum level of HBV DNA was only 950 IU/mL. This case demonstrates important clinical problems connected with HBV infection in immunocompromised persons.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            [Viral hepatitis B in a patient with follicular lymphoma treated with biological therapy]. Reactivation, recurrence or acute infection with hepatitis B virus (HBV) represent severe complications of biological therapy. Reported is a case of a 58-year-old female treated in the past with cytostatics and rituximab for follicular lymphoma , in whom HBV infection was detected during a follow-up of the contacts of her partner diagnosed with acute viral hepatitis B. At the beginning , the patient had a very high serum level of HBV DNA ( 4.3 × 108 IU/mL ) and therefore she was treated with combined antiviral therapy ( lamivudine and tenofovir ) . After 10 months, the serum level of HBV DNA decreased significantly (3,100 IU/mL) and the combined antiviral therapy was switched to monotherapy with tenofovir. Another 5 months later, the serum level of HBV DNA was only 950 IU/mL. This case demonstrates important clinical problems connected with HBV infection in immunocompromised persons.

            ### Response:
            rituximab, lamivudine, tenofovir
            